Health care startups that raised Series C in the United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Delix Therapeutics | Boston | Series C | $100.0M | 2026-11-09 |
| GT Metabolic Solutions | Saint Michael | Series C | $17.1M | 2026-10-28 |
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| Archy | San Jose | Series C | $50.0M | 2026-09-11 |
| PatientIQ | Chicago | Series C | $30.0M | 2026-09-03 |
| ImmunoPhotonics | St Louis | Series C | $10.1M | 2026-09-01 |
| Channel Medsystems | Berkeley | Series C | $30.0M | 2026-08-20 |
| Bridge to Life | Northbrook | Series C | $110.0M | 2026-08-12 |
8 rows of the CSV in 5 of its 18 columns.
- The 620 health care startups in the United States whose last round is Series C have raised $59.6B in total.
- 59 of them closed their most recent round in the last 12 months, $3.7B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- RA Capital Management is an investor in 10 of them, more than any other fund.
- Biotech is the most common other sector, with 312 companies (50%).
- 6% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (39% of companies with a recorded size).
- 8 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 620| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| GT Metabolic Solutions | GT Metabolic Solutions develops an incision-less bypass technology for bariatric and metabolic surgery. | Health care | Saint Michael | Series C | $17.1M | 2026-10-28 | $32.1M | HealthTech Capital, Ceros Capital Markets | 11 to 50 | 2021 |
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| Archy | Archy provides dental practice management software that unifies patient care, communication, and reporting. | Artificial intelligence | San Jose | Series C | $50.0M | 2026-09-11 | $93.0M | Bessemer Venture Partners, CRV, Alven +2 | 101 to 250 | 2021 |
| PatientIQ | PatientIQ provides a healthcare data platform for collecting, analyzing, and integrating patient outcomes data. | Artificial intelligence | Chicago | Series C | $30.0M | 2026-09-03 | $56.2M | August Capital, Health Enterprise Partners | 51 to 100 | 2016 |
| ImmunoPhotonics | ImmunoPhotonics is a biotechnology company that develops cancer immunotherapies to stimulate immune responses against tumors. | Biotech | St Louis | Series C | $10.1M | 2026-09-01 | $42.0M | TCA Venture Group, Cultivation Capital, Arch Grants +1 | 11 to 50 | 2012 |
| Channel Medsystems | Channel Medsystems manufactures cryotherapy devices for endometrial cryoablation procedures. | Health care | Berkeley | Series C | $30.0M | 2026-08-20 | $97.9M | Third Point Ventures, Green Park & Golf Ventures, Longwood Fund +1 | 11 to 50 | 2009 |
| Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| InStride Health | InStride Health provides evidence-based OCD and anxiety treatment to children and teenagers. | Health care | Boston | Series C | $30.0M | 2026-06-15 | $86.0M | General Catalyst, .406 Ventures, Mass General Brigham Ventures +2 | 251 to 500 | 2021 |
| Stepful | Stepful offers online training and certification programs for healthcare careers. | Education | New York | Series C | $55.0M | 2026-06-08 | $111.0M | Y Combinator, Unpopular Ventures, Reach Capital +2 | 11 to 50 | 2021 |
| CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Boston | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Crown Affair | Crown Affair sells haircare products and hair tools for daily maintenance, styling, and scalp care. | Health care | New York | Series C | $5.0M | 2026-05-07 | $24.4M | Alumni Ventures, Greycroft, Brand Foundry Ventures +2 | 11 to 50 | 2019 |
| Iterative Health | Iterative Health develops technology to improve patient access to healthcare across different socioeconomic and geographic areas. | Artificial intelligence | Cambridge | Series C | $77.0M | 2026-04-30 | $268.6M | Plug and Play, Alumni Ventures, Insight Partners +1 | 251 to 500 | 2017 |
| Kashable | Kashable provides employer-sponsored lending and financial wellness services to employees. | Fintech | New York | Series C | $60.0M | 2026-04-27 | $472.6M | Revolution, Alpaca VC, Moneta VC +2 | 101 to 250 | 2013 |
| AcuityMD | AcuityMD provides AI-powered data analysis to help companies make informed commercial decisions in healthcare. | Artificial intelligence | Boston | Series C | $80.0M | 2026-04-21 | $163.0M | Redpoint, Benchmark, ICONIQ Growth +2 | 251 to 500 | 2019 |
| Tava Health | Tava Health is a digital mental health company that connects individuals with licensed therapists online. | Health care | Salt Lake City | Series C | $40.0M | 2026-04-21 | $73.0M | Pear VC, Kickstart, SaaS Ventures +2 | 101 to 250 | 2019 |
| Summus Global | Summus Global operates a virtual specialist platform that offers personalized medical advice. | Health care | New York | Series C | $20.0M | 2026-04-07 | $84.3M | Teamworthy Ventures, Outsiders Fund, Sator Grove Holdings +1 | 51 to 100 | 2015 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Endogenex | Endogenex develops an endoscopic procedure to help type 2 diabetes patients control blood glucose levels. | Health care | Plymouth | Series C | $50.0M | 2026-03-25 | $163.0M | Longitude Capital, Hatteras Venture Partners, Sante Ventures +1 | 11 to 50 | 2017 |
| Adonis | Adonis provides revenue cycle management software for healthcare organizations. | Artificial intelligence | New York | Series C | $40.0M | 2026-03-25 | $93.9M | General Catalyst, Point72 Ventures, Bling Capital +1 | 101 to 250 | 2022 |
| Moxie | Moxie provides software for managing MedSpa operations, including compliance, marketing, and patient management. | Health care | New York | Series C | $25.0M | 2026-03-10 | $50.7M | SignalFire, Boulton & Watt | 101 to 250 | 2022 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Colossal Biosciences Unicorn | Colossal Biosciences uses gene editing technology to pursue de-extinction of species. | Biotech | Austin | Series C | $60.0M | 2026-02-03 | $628.1M | Boost VC, Capital Factory, Climate Capital | 101 to 250 | 2021 |
| Beacon Therapeutics | Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. | Biotech | Alachua | Series C | $75.0M | 2026-01-08 | $365.1M | Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 | 101 to 250 | 2023 |
| Codoxo | Codoxo uses generative and self-learning AI to improve healthcare payment integrity. | Artificial intelligence | Duluth | Series C | $35.0M | 2025-12-17 | $49.7M | Service Provider Capital, QED Investors, Sands Capital Ventures +2 | 101 to 250 | 2017 |
Table 1. Health care startups that raised Series C in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 620.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 3 | Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| 4 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 5 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 6 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 7 | CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| 8 | AcuityMD | AcuityMD provides AI-powered data analysis to help companies make informed commercial decisions in healthcare. | Artificial intelligence | Boston | Series C | $80.0M | 2026-04-21 | $163.0M | Redpoint, Benchmark, ICONIQ Growth +2 | 251 to 500 | 2019 |
| 9 | Iterative Health | Iterative Health develops technology to improve patient access to healthcare across different socioeconomic and geographic areas. | Artificial intelligence | Cambridge | Series C | $77.0M | 2026-04-30 | $268.6M | Plug and Play, Alumni Ventures, Insight Partners +1 | 251 to 500 | 2017 |
| 10 | BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
Table 2. Health care startups that raised Series C in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 10 | 2% | 2 | Delix Therapeutics, Terrestrial Bio |
| 2 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 9 | 1% | 2 | Prellis Biologics, Loyal |
| 3 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 8 | 1% | 2 | BigHat Biosciences, Ratio Therapeutics |
| 4 | Y Combinator | Startup accelerator | Mountain View, United States | 8 | 1% | 1 | Stepful |
| 5 | Alumni Ventures | Angel group | Manchester, United States | 8 | 1% | 2 | Crown Affair, Iterative Health |
| 6 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 7 | 1% | 1 | BigHat Biosciences |
| 7 | General Catalyst | Venture capital firm | San Francisco, United States | 7 | 1% | 2 | InStride Health, Adonis |
| 8 | Insight Partners | Private equity firm | New York, United States | 7 | 1% | 1 | Iterative Health |
| 9 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 7 | 1% | ||
| 10 | Cormorant Asset Management | Hedge fund | Boston, United States | 6 | 1% | 2 | Triveni Bio, Akura Medical |
| 11 | OrbiMed | Private equity firm | New York, United States | 6 | 1% | 2 | Triveni Bio, Aspen Neuroscience |
| 12 | Google Ventures | Corporate venture arm | San Francisco, United States | 6 | 1% | 2 | Cerevance, Aspen Neuroscience |
| 13 | Invus | Private equity firm | New York, United States | 5 | 1% | 1 | Triveni Bio |
| 14 | Polaris Partners | Private equity firm | Boston, United States | 5 | 1% | 1 | Triveni Bio |
| 15 | .406 Ventures | Venture capital firm | Boston, United States | 5 | 1% | 1 | InStride Health |
Table 3. Health care startups that raised Series C in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 312 | 50% | $35.6B |
| Software | 142 | 23% | $15.9B |
| Artificial intelligence | 60 | 10% | $9.6B |
| Fintech | 26 | 4% | $3.2B |
| Hardware | 23 | 4% | $2.1B |
| Commerce | 20 | 3% | $623.0M |
| Education | 6 | 1% | $445.3M |
| Cybersecurity | 4 | 1% | $189.8M |
| Energy | 4 | 1% | $241.8M |
Table 4. Health care startups that raised Series C in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 620 | 100% | $30.0M |
Table 5. Health care startups that raised Series C in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 54 | 9% |
| New York | 40 | 6% |
| San Diego | 31 | 5% |
| Boston | 29 | 5% |
| Cambridge | 26 | 4% |
| Menlo Park | 17 | 3% |
| Austin | 15 | 2% |
| Seattle | 14 | 2% |
| Irvine | 11 | 2% |
| Mountain View | 11 | 2% |
| Palo Alto | 10 | 2% |
| Los Angeles | 9 | 1% |
Table 6. Health care startups that raised Series C in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 3% | $115.0M |
| October 2026 | 3 | 5% | $161.1M |
| September 2026 | 8 | 14% | $514.1M |
| August 2026 | 3 | 5% | $155.0M |
| July 2026 | 6 | 10% | $601.0M |
| June 2026 | 7 | 12% | $540.0M |
| May 2026 | 3 | 5% | $25.0M |
| April 2026 | 7 | 12% | $407.4M |
| March 2026 | 10 | 17% | $422.0M |
| February 2026 | 3 | 5% | $160.0M |
| January 2026 | 4 | 7% | $395.0M |
| December 2025 | 2 | 3% | $88.0M |
| November 2025 | 1 | 2% | $115.0M |
Table 7. Health care startups that raised Series C in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 56 | 9% | $3.5B |
| 2025 | 58 | 9% | $3.7B |
| 2024 | 46 | 7% | $3.1B |
| 2023 | 36 | 6% | $2.0B |
| 2022 | 52 | 8% | $3.1B |
| 2021 | 60 | 10% | $3.8B |
Table 8. Health care startups that raised Series C in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 7 | 1% |
| 2020 to 2022 | 31 | 5% |
| 2015 to 2019 | 198 | 32% |
| 2010 to 2014 | 148 | 24% |
| Before 2010 | 233 | 38% |
Table 9. Health care startups that raised Series C in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 60 | 10% |
| 11 to 50 | 241 | 39% |
| 51 to 100 | 114 | 19% |
| 101 to 250 | 124 | 20% |
| 251 to 500 | 39 | 6% |
| 501 to 1,000 | 26 | 4% |
| 1,001 to 5,000 | 6 | 1% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 4 | 1% |
Table 10. Health care startups that raised Series C in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series C and its headquarters is in the United States. On 16 November 2026 that is 620 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 620 rows: 45 have no round amount, 0 no city and 37 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in the United States whose last round is Series C are on the list?
- 620, in the file dated 16 November 2026. 59 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 620 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.